FDA Gives Approval for First-of-Its-Kind Device

FDA gives approval for first-of-its-kind device

FRANKFORT, Ky. (KT) – The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind device for the treatment of adult patients who have locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields (TTFields), to the abdomen. TTFields work by physically disrupting the rapid cell division that is characteristic of…

New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

FDA approves Israeli development for pancreatic cancer treatment

The Israeli company Novocure announced the approval by the US Food and Drug Administration of another of its products for the treatment of pancreatic cancer. Novocure was based on the late Professor Yoram Palti’s pioneering invention for treating cancer by directing electric fields at the tumor to prevent cells in the tumor from dividing. The […]